Title: Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
Journal: The Journal of pharmacology and experimental therapeutics 20150401
Title: Antitumor progression potential of morusin suppressing STAT3 and NFκB in human hepatoma SK-Hep1 cells.
Journal: Toxicology letters 20150122
Title: Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3.
Journal: Chemico-biological interactions 20140425
Title: Resveratrol suppresses cell proliferation via inhibition of STAT3 phosphorylation and Mcl-1 and cIAP-2 expression in HTLV-1-infected T cells.
Journal: Leukemia research 20131201
Title: Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.
Journal: Cell cycle (Georgetown, Tex.) 20120115
Title: NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
Journal: Liver international : official journal of the International Association for the Study of the Liver 20120101
Title: A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
Journal: PloS one 20120101
Title: Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.
Journal: Human molecular genetics 20111101
Title: α4β2 nicotinic receptors partially mediate anti-inflammatory effects through Janus kinase 2-signal transducer and activator of transcription 3 but not calcium or cAMP signaling.
Journal: Molecular pharmacology 20110101
Title: Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.
Journal: BMC cancer 20110101
Title: STAT3 activation in monocytes accelerates liver cancer progression.
Journal: BMC cancer 20110101
Title: A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.
Journal: Biochemical pharmacology 20100515
Title: A novel method in order to evaluate the efficacies and the safeties of new drugs for hepatocellular carcinoma with loss of transforming growth factor-beta signaling.
Journal: Hepatology (Baltimore, Md.) 20091201
Title: Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities.
Journal: Chembiochem : a European journal of chemical biology 20090817
Title: The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.
Journal: Oncogene 20090219
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Title: Siddiquee K, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6.
Title: Lin L, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene. 2009 Feb 19;28(7):961-72.
Title: Zhou C, et al. STAT3 upregulation in pituitary somatotroph adenomas induces hypersecretion. J Clin Invest. 2015 Apr;125(4):1692-702
